Exhibit 99.2

Arcadia Biosciences, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)
|
|
As of December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
259 |
|
|
$ |
4,242 |
|
Short-term investments |
|
|
4,304 |
|
|
|
— |
|
Accounts receivable and other receivables, net of allowance for credit loss |
|
|
425 |
|
|
|
1,175 |
|
Inventories |
|
|
1,212 |
|
|
|
904 |
|
Note receivable — current, net of allowance for credit losses (Note 8) |
|
|
— |
|
|
|
1,894 |
|
Prepaid expenses and other current assets |
|
|
156 |
|
|
|
931 |
|
Current assets of discontinued operations — GoodWheat |
|
|
— |
|
|
|
96 |
|
Total current assets |
|
|
6,356 |
|
|
|
9,242 |
|
Property and equipment, net |
|
|
8 |
|
|
|
41 |
|
Right of use assets |
|
|
— |
|
|
|
137 |
|
Intangible assets, net |
|
|
39 |
|
|
|
39 |
|
Note receivable — noncurrent, net of allowance for credit losses (Note 8) |
|
|
— |
|
|
|
3,966 |
|
Other noncurrent assets |
|
|
143 |
|
|
|
92 |
|
Total assets |
|
$ |
6,546 |
|
|
$ |
13,517 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
1,789 |
|
|
$ |
2,108 |
|
Amounts due to related parties |
|
|
— |
|
|
|
30 |
|
Operating lease liability — current |
|
|
— |
|
|
|
155 |
|
Other current liabilities |
|
|
270 |
|
|
|
270 |
|
Total current liabilities |
|
|
2,059 |
|
|
|
2,563 |
|
Common stock warrant and option liabilities |
|
|
347 |
|
|
|
2,731 |
|
Other noncurrent liabilities |
|
|
— |
|
|
|
2,000 |
|
Total liabilities |
|
|
2,406 |
|
|
|
7,294 |
|
Commitments and contingencies (Note 14) |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, $0.001 par value—150,000,000 shares authorized as of |
|
|
65 |
|
|
|
65 |
|
Additional paid-in capital |
|
|
285,292 |
|
|
|
285,036 |
|
Accumulated deficit |
|
|
(281,217 |
) |
|
|
(278,878 |
) |
Total stockholders' equity |
|
|
4,140 |
|
|
|
6,223 |
|
Total liabilities and stockholders’ equity |
|
$ |
6,546 |
|
|
$ |
13,517 |
|